Ranbaxy launches anti-acne drug in the US market
   
Quotes

Ranbaxy launches anti-acne drug in the US market

Last Updated: Monday, November 26, 2012, 14:16
 
 Comment 0
 
New Delhi: Drug major Ranbaxy Laboratories Monday said it has launched Absorica capsules, used in treating acne, in the US market.

Ranbaxy Laboratories Inc (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Ltd (RLL), Monday announced the launch of Absorica (Isotretinoin) capsules, a product that is licensed from Cipher Pharmaceuticals Inc of Mississauga, Ontario, Ranbaxy said in a statement.

According to March 2012 IMS MAT data, sales of Absorica (isotretinoin) capsules stood at USD 400 million in the US market.

"... Absorica will be the flagship brand of the Ranbaxy dermatology product portfolio in the US," Ranbaxy Laboratories Inc Senior Director Ashish Anvekar said.

Absorica, which is indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older, can be given without regards to meals, the company said.

According to an analyst, the launch of Absorica would greatly benefit Ranbaxy as there are only 2-3 players currently selling the product in the US market.

RLI, which is based in Jacksonville (Florida), is engaged in the sale and distribution of branded prescription products in the US healthcare system.

Shares of Ranbaxy were trading at Rs 497.50 on the BSE in the afternoon trade, up 0.31 percent from its previous close.

PTI



First Published: Monday, November 26, 2012, 14:16


Comments


comments powered by Disqus
New Vento 2015
New Vento 2015
Audi all-new SUV Q3
Audi all-new SUV Q3
Indian Billionaire Daughters
Indian Billionaire Daughters
TOP 5  happy cities of India
TOP 5 happy cities of India
Forbes Top 10 Billionaires 2015
Forbes Top 10 Billionaires 2015

Web Wrap
Contact Us : Privacy Policy : Legal Disclaimer
Copyright © Zee Media Corporation Ltd. All rights reserved